Sector Update: Health Care Stocks Higher Late Afternoon

MT NewswiresFeb 5 15:52 ET

Acrivon Therapeutics Says FDA Grants Its ACR-368 OncoSignature Assay Breakthrough Device Designation

MT NewswiresFeb 5 10:43 ET

Acrivon Therapeutics Granted FDA Breakthrough Device Designation For ACR-368 OncoSignature Assay In Endometrial Cancer

BenzingaFeb 5 08:01 ET

Express News | Acrivon Therapeutics Announces FDA Has Granted Breakthrough Device Designation for Acr-368 Oncosignature Assay for Endometrial Cancer

ReutersFeb 5 08:00 ET

Acrivon Therapeutics Announces FDA Has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

Acrivon TherapeuticsFeb 5 00:00 ET

Acrivon Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow JonesJan 31 10:32 ET · Ratings